Confident Investing Starts With TipRanks Premium

Get 55% Off
TipRanks
Go Ultimate55% OFF

Illumina (ILU) Price & Analysis

ILU Stock Chart & Stats

No data to display
Day’s Range
N/A
52-Week Range
N/A
Previous Close
N/A
Volume
N/A
Average Volume (3M)
N/A
Market Cap
CHF 29.36B
Enterprise Value
CHF 42.56B
Total Cash (Recent Filing)
CHF 1.34B
Total Debt (Recent Filing)
CHF 2.23B
Price to Earnings (P/E)
40.1
Beta
N/A
Next Earnings
Feb 11, 2027
EPS Estimate
1.26
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Clinical Consumables Growth

Strong clinical consumables growth indicates expanding adoption of sequencing in diagnostics and clinical trials, a potentially durable demand stream. Continued mid-teens growth and a rich pipeline of tests can support recurring consumables revenue as clinical workflows become more established.

Recurring Consumables Base

A growing high-throughput installed base strengthens Illumina’s recurring-revenue model because customers must purchase consumables to use deployed instruments. Rising utilization and NovaSeq X adoption can create durable pull-through revenue beyond the initial hardware sale.

Cash Generation And Margins

Robust operating and free cash flow, together with restored profitability, improves Illumina’s ability to fund innovation, service debt, and return capital without relying solely on external financing. The strong earnings-to-cash conversion also supports the quality of the recent recovery.

Bears Say

Research Market Declines

Weakness in research and applied consumables creates a meaningful drag on revenue because these markets remain important sources of sequencing demand. Continued declines through 2026 could offset clinical growth, reduce instrument utilization, and make consolidated growth more dependent on a narrower customer segment.

Pricing And Cost Headwinds

Persistent input-cost and pricing pressure can limit margin expansion even as revenue grows. Tariffs, shipping costs, and lower transition pricing may reduce the economic benefit of NovaSeq X adoption, requiring continued operational discipline to preserve the company’s recently improved profitability.

China Trade Uncertainty

Regulatory and trade uncertainty in China can disrupt customer access, sales execution, and instrument or consumables demand in an important geographic market. The absence of a determined impact does not remove the risk that policy developments could constrain growth or increase operating complexity.

Illumina News

ILU FAQ

What is Illumina’s market cap?
Illumina’s market cap is CHF29.36B.
When is Illumina’s upcoming earnings report date?
Illumina’s upcoming earnings report date is Feb 11, 2027 which is in 102 days.
How were Illumina’s earnings last quarter?
Illumina released its earnings results on Oct 29, 2026. The company reported CHF1.186 earnings per share for the quarter, beating the consensus estimate of CHF1.117 by CHF0.069.
Is Illumina overvalued?
Not enough analysts have published a price target to calculate whether the price is overvalued.
Does Illumina pay dividends?
Illumina does not currently pay dividends.
What is Illumina’s EPS estimate?
Illumina’s EPS estimate is 1.26.
What happened to Illumina’s price movement after its last earnings report?
Illumina reported an EPS of CHF1.186 in its last earnings report, beating expectations of CHF1.117. Following the earnings report the stock price went same ―.
Which hedge fund is a major shareholder of Illumina?
Currently, no hedge funds are holding shares in CH:ILU
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology